Patients preferences for generic and branded over-the-counter medicines: An adaptive conjoint analysis approach

Patient

Volumn 2, Issue 4, 2009, Pages 243-255

  Halme, Merja ^c   Linden, Kari ^a   Kääriä, Kimmo ^b  

^a PFIZER INC   (United States)

^b HELSINKI SCHOOL OF ECONOMICS   (Finland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; NON PRESCRIPTION DRUG;

ARTICLE; DRUG COST; HEALTH BEHAVIOR; HEALTH CARE PERSONNEL; HUMAN; PATIENT ATTITUDE; PRIORITY JOURNAL; SOCIOECONOMICS;

EID: 77953380725     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.2165/11314130-000000000-00000     Document Type: Article

References (64)

1. Ascione FJ, Kirking DM, Gaither CA, et al. Historical overview of generic medication policy. J Am Pharm Ass 2001; 41: 567-577
2. Simoens S, De Bruyn K, Bogaert M, et al. Pharmaceutical policy regarding generic drugs in Belgium. Pharmacoeconomics 2005; 23 (8): 755-766
3. Lexchin J. The effect of generic competition on the price of brand-name drugs. Health Pol 2004; 68: 47-54
4. HeikkiläR, MäntyselkäP, Hartikainen-Herranen K, et al. Customers' and physicians' opinions of and experiences with generic substitution during the first year in Finland. Health Pol 2007; 82: 366-374
5. Buzzelli C, Kangasharju A, Linnosmaa I, et al. Impact of generic substitution on pharmaceutical prices and expenditures in OECD countries. J Pharm Finance Econ Pol 2006; 5: 41-63
6. Andersson KA, Petzold MG, Allebeck P, et al. Influence of mandatory generic substitution on pharmaceutical sales patterns: a national study over five years. BMC Health Serv Res 2008; 8: 50
7. Andersson K, Sonesson C, Petzold M, et al. What are the obstacles to generic substitution? An assessment of the behavior of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 2005; 14: 341-348
8. Gaither CA, Kirking DM, Ascione FJ, et al. Consumers' views on generic medications. J Am Pharm Ass 2001; 41: 729-736
9. Canadian Health Services Research Foundation. Myth: generic drugs are lower quality and less safe than brandname drugs. J Health Serv Res Pol 2007; 12: 255-256
10. Vogt F, Schwappach DLB, Bridges JFP. Accounting for tastes: a German perspective on the inclusion of patient preferences in healthcare. Pharmacoeconomics 2006; 24 (5): 419-423
11. Sevdalis N, Harvey N. Predicting preferences: a neglected aspect of shared decision-making. Health Expect 2006; 9: 245-251
12. Johnson FR. Why not ask? Measuring patient preferences for healthcare decision making. Patient 2008; 1 (4): 245-248
13. Hawley ST. Conjoint analysis: a 'new' way to evaluate patients' preferences. Patient 2008; 1 (4): 255-257
14. Bridges JFP. Stated preference methods in health care evaluation: an emerging methodological paradigm in health economics. Appl Health Econ Health Pol 2003; 2 (4): 213-224
15. Bridges JFP. Future challenges for the economic evaluation of healthcare: patient preferences, risk attitudes and beyond. Pharmacoeconomics 2005; 23 (4): 317-321
16. Mantovani LG, Monzini MS, Mannucci PM, et al. Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment. Haemophil 2005; 11: 589-597
17. Johnsson G, Ställberg B, Tornling G, et al. Asthma treatment preference study: a conjoint analysis of preferred drug treatments. Chest 2004; 125: 916-923
18. Wellman G, Pathak D, Schommer J, et al. Drug attributes and patient out-of-pocket cost impact on preference: conjoint analysis of physicians, pharmacists, and consumers. J Pharm Market Manag 2003; 15: 47-61
19. Fraenkel L, Bogardus ST, Concato J, et al. Treatment options in knee osteoarthritis: the patient's perspective. Arch Intern Med 2004; 164: 1299-1304 (Pubitemid 38828880)
20. Bishai D, Brice R, Girod I, et al. Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine. Pharmacoeconomics 2007; 25 (2): 143-154
21. Sandri H, MacKeigan LD, Leiter LA, et al. Willingness to pay for inhaled insulin: a contingent valuation approach. Pharmacoeconomics 2005; 23 (12): 1215-1227
22. Himmel W, Simmenroth-Nayda A, Niebling W, et al. What do primary care patients think about generic drugs? Int J Clin Pharmacol Ther 2005; 43: 472-479
23. Mott DA, Cline RR. Exploring generic drug use behavior: the role of prescribers and pharmacists in the opportunity for generic drug use and generic substitution. Med Care 2002; 40: 662-674
24. Aronson JK. Risk perception in drug therapy. Br J Pharmacol 2006; 62: 135-137
25. Ganther JM,Kreling DH. Consumer perceptions of risk and required cost savings for generic prescription drugs. J Am Pharm Ass 2000; 40: 378-383
26. Kellett N, West F, Finlay AY. Conjoint analysis: a novel, rigorous tool for determining patient preferences for topical antibiotic treatment for acne. A randomised controlled study. Br J Dermatol 2006; 154: 524-532
27. Atella V, Schafheutle E, Noyce P, et al. Affordability of medicines and patients' cost-reducing behavior: empirical evidence based on SUR estimates from Italy and the UK. Appl Health Econ Health Pol 2005; 4: 23-35
28. Kjoenniksen I, Lindbaek M, Gerd Granas A. Patients' attitudes towards and experiences of generic drug substitution in Norway. Pharm World Sci 2006; 28: 284-289
29. Hassali HA, Kong DCM, Stewart K. Generic medicines: perceptions of consumers in Melbourne, Australia. Int J Pharm Pract 2005; 13: 257-264 (Pubitemid 41746433)
30. Waber RL, Shiv B, Carmon Z, et al. Commercial features of placebo and therapeutic efficacy. JAMA 2008; 299: 1016-1017
31. Rao AR, Monroe KB. The effect of price, brand name, and store name on buyers' perceptions of product quality. J Market Res 1989; 26: 351-357
32. Zheng Zhou K, Su C, Bao Y. A paradox of price-quality and market efficiency: a comparative study of the US and China markets. Int J Res Market 2002; 19: 349-365
33. Singh J, Cuttler L, Shin M, et al. Medical decision-making and the patient: understanding preference patterns for growth hormone therapy using conjoint analysis. Med Care 1998; 36 (8 Suppl.): AS31-45
34. O'Brien B. The effect of patient charges on the utilisation of prescription medicines. J Health Econ 1989; 8: 109-132
35. Wittink DR, Cattin P. Commercial use of conjoint analysis: an update. J Market 1989; 53: 91-96
36. Green PE, Srinivasan V. Conjoint analysis in consumer research: issues and outlook. J Consum Res 1978; 5: 103-123
37. Hay JW. Conjoint analysis in pharmaceutical research. J Manag Care 2002; 8: 206-208
38. Beusterien KM, Dziekan K, Flood E, et al. Understanding patient preferences for HIV medications using adaptive conjoint analysis: feasibility assessment. Value Health 2005; 8: 453-461
39. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000; 320: 1530-1533
40. Antonov K, Isacson D. Use of analgesics in Sweden: the importance of sociodemographic factors, physical fitness, health and health-related factors, and working conditions. Soc Sci Med 1996; 42: 1473-1481
41. Turunen JHO, MäntyselkäPT, Kumpusalo EA, et al. Frequent analgesic use at population level: prevalence and patterns of use. Pain 2005; 115: 374-381
42. Antonov KIM, Isacson DGL. Prescription and non-prescription analgesic use in Sweden. Ann Pharmacother 1998; 32: 485-494
43. Rosvold EO. Self-reported use of medicines among university students in Oslo, Norway. Norsk Epidemiol 2008; 18: 195-199
44. Häkkinen U, Järvelin M-L, Rosenqvist G, et al. Health, schooling and lifestyle among young adults in Finland. Health Econ 2006; 15: 1201-1216
45. Zhang B, Vartmill C, Ferrence R. The role of spending money and drinking alcohol in adolescent smoking. Addict 2007; 103: 310-319
46. Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value tradeoffs. New York: John Wiley and Sons, 1976
47. Green PE, Krieger AM, Wind Y. Thirty years of conjoint analysis: reflections and prospects. Interf 2001; 3: S56-73
48. Green PE, Krieger AM, Agarwal MK. Adaptive conjoint analysis: some cautions and caveats. JMarket 1991; 54: 3-19
49. Malhotra NK, Birks DF. Marketing research: an applied approach. 2nd European ed. New York: Pearson Education, 2003
50. Sawtooth Software. ACA/Web technical paper [online]. Available from URL: http://sawtoothsoftware.com [Accessed 2008 Feb 25]
51. Ho FN, Murch JD, Soo Ong B, et al. Consumer satisfaction with OTC drugs: an analysis using the confirmation/ disconfirmation model. Health Market Q 1997; 15: 103-117
52. Powpaka S. Consumers' brand choice of pharmaceutical products during economic depression: an empirical investigation. J Pharm Market Manag 2001; 14: 27-61
53. Zaichkowsky JL. Measuring the involvement construct. J Consum Res 1985; 12: 341-352
54. Gore P, Madhavan S, McClung G, et al. Consumer involvement in non-prescription medicine purchase decisions. J Health Care Market 1994; 14: 16-23
55. Green PE, Krieger AM. Segmenting markets with conjoint analysis. J Market 1991; 55: 20-31
56. Wedel M, Kamakura W. Market segmentation: conceptual and methodological foundations. 2nd ed. Boston (MA): Kluwer Academic Publishers, 1998
57. Valeeva NI, Meuwissen MPM, Bergevoet RHM, et al. Improving food safety at the dairy farm level: farmers' and experts' perceptions. Rev Agricult Econ 2005; 27: 574-592
58. Stott AW, Milne CE, Goddard PJ, et al. Projected effect of alternative management strategies on profit and animal welfare in extensive sheep production systems in Great Britain. Livestock Product Sci 2005; 97: 161-171
59. Rogers EM. Diffusion of innovations. 4th ed. New York: The Free Press, 1995
60. Contoyannis P, Hurley J, Grootendorst P, et al. Estimating the price elasticity of expenditure for prescription drugs in the presence of non-linear price schedules: an illustration from Quebec, Canada. Health Econ 2005; 14: 909-923
61. Suh D. Trends of generic substitution in community pharmacies. Pharm World Sci 1999; 21: 260-265
62. Akcura MT, Gönul FF, Petrova E. Consumer learning and brand valuation: an application on over-the-counter drugs. Market Sci 2004; 23: 156-169
63. Frank RG, Salkever DS. Generic entry and the pricing of pharmaceuticals. J Econ Manag Strat 1997; 6: 75-90
64. Domino ME, Salkever DS. Price elasticity and pharmaceutical selection: the influence of managed care. Health Econ 2003; 12: 565-586